- Report
- June 2026
- 200 Pages
Global
From €2823EUR$2,990USD£2,357GBP
- Report
- November 2026
- 282 Pages
Global
From €5524EUR$5,850USD£4,611GBP
- Report
- February 2026
- 250 Pages
Global
From €4240EUR$4,490USD£3,539GBP
- Report
- February 2026
- 250 Pages
Global
From €4240EUR$4,490USD£3,539GBP
- Report
- February 2026
- 200 Pages
Global
From €7544EUR$7,990USD£6,298GBP
- Report
- November 2023
- 135 Pages
Global
From €3777EUR$4,000USD£3,153GBP
- Clinical Trials
- April 2025
- 50 Pages
Global
From €1416EUR$1,500USD£1,182GBP
- Report
- June 2025
- 150 Pages
Global
From €3541EUR$3,750USD£2,956GBP
- Report
- September 2024
- 343 Pages
Global
From €7507EUR$7,950USD£6,266GBP
- Report
- July 2024
- 150 Pages
Global
From €3541EUR$3,750USD£2,956GBP
- Report
- June 2025
- 400 Pages
Global
From €4673EUR$4,949USD£3,901GBP
- Report
- March 2023
- 147 Pages
Global
From €4673EUR$4,949USD£3,901GBP
- Report
- May 2024
- 135 Pages
Global
From €3776EUR$3,999USD£3,152GBP
- Report
- May 2024
- 137 Pages
Global
From €3776EUR$3,999USD£3,152GBP
- Report
- January 2023
- 85 Pages
Europe
From €1416EUR$1,500USD£1,182GBP
- Report
- September 2025
- 150 Pages
Global
From €4202EUR$4,450USD£3,508GBP
- Report
- September 2025
- 112 Pages
Global
From €3500EUR$3,971USD£3,024GBP
- Report
- January 2024
- 114 Pages
United States
€3305EUR$3,500USD£2,759GBP
- Report
- January 2024
- 156 Pages
United States
€3588EUR$3,800USD£2,995GBP
- Report
- January 2024
- 109 Pages
United States
€3305EUR$3,500USD£2,759GBP

Tiotropium is a long-acting anticholinergic drug used to treat chronic obstructive pulmonary disease (COPD). It is a bronchodilator, meaning it relaxes the muscles in the airways, allowing more air to flow in and out of the lungs. It is available in both an inhaler and a dry powder inhaler. Tiotropium is the only long-acting anticholinergic approved for the treatment of COPD. It is also used to treat asthma and other respiratory conditions.
Tiotropium is a popular drug in the respiratory drugs market, as it is effective in treating COPD and other respiratory conditions. It is also well-tolerated, with few side effects. It is available in both generic and brand-name forms, making it accessible to a wide range of patients.
Some companies in the Tiotropium market include Boehringer Ingelheim, GlaxoSmithKline, and Novartis. Show Less Read more